Status:
RECRUITING
Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
Lead Sponsor:
Jinling Hospital, China
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aims to conduct a multicenter, prospective, randomized clinical trial to scientifically evaluate the safety and efficacy of different perioperative sedation methods during endovascular thro...
Detailed Description
In the perioperative period of endovascular thrombectomy, the main sedation options are midazolam (MDZ) and dexmedetomidine (DEX). Research has shown that both sedation methods have their advantages a...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Presenting with symptoms of acute ischemic stroke
- CTA or MRA confirmed occlusion of the anterior circulation (intracranial carotid artery or M1, M2 segment of the middle cerebral artery)
- Randomization finished within 24 hours of symptom onset or time last know well
- Pre-stroke mRS score ≤2
- NIHSS score ≥6 at the time of randomization
- ASPECTS value ≥3
- Informed consent signed
Exclusion
- General exclusion criteria
- Pregnant or lactating women
- Known allergy to contrast agents or nitinol devices
- Known allergy to midazolam or other benzodiazepines
- Known allergy to dexmedetomidine or its components
- Planned to receive general anesthesia for EVT
- Uncontrolled hypertension or hypotension (defined as systolic blood pressure \>185 mmHg or \< 90 mmHg, diastolic blood pressure \>110 mmHg or \< 60 mmHg)
- Second-degree or third-degree heart blockage or bradyarrhythmia with a baseline heart rate lower than 50 beats/min
- Any major surgery or serious trauma within 14 days
- Known genetic or acquired bleeding diathesis (platelet count \< 100\\\*109 /L, activated partial thromboplastin time \> 50 s or international normalized ratio \> 1.7)
- Blood glucose \<2.8 or \> 22.2 mmol/L
- Severe renal insufficiency (defined as glomerular filtration rate \<30 ml/min or serum creatinine \>220 mmol/L (2.5mg/dl))
- Receiving hemodialysis or peritoneal dialysis
- Life expectancy less than 1 year
- Severe agitation or seizures
- Clinical manifestations of central nervous system vasculitis
- Premorbid neurological disease or mental disorders confounding evaluation
- Unwilling to be followed up within 90 days
- Participation in other interventional randomized clinical trials Imaging exclusion criteria
- 1\. Evidence of intracranial hemorrhage on CT or MRI 2. Cerebellar infarction with obvious space-occupying effects and fourth ventricle compression on CT or MRI 3. Any untreated or incompletely treated intracranial aneurysm or any intracranial vascular malformation 4. Bilateral occlusion or multiple intracranial vessels occlusions 5. Intracranial tumors (with mass effect)
Key Trial Info
Start Date :
November 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 13 2026
Estimated Enrollment :
810 Patients enrolled
Trial Details
Trial ID
NCT06139692
Start Date
November 21 2023
End Date
June 13 2026
Last Update
November 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinling Hospital, Medical School of Nanjing University
Nanjing, None Selected, China
2
The General Hospital of Western Theater Command PLA
Chengdu, China